Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with serologically confirmed chronic hepatitis C~* Participants using and accepting a double method of contraception~Exclusion Criteria:~* Participants not approved by the national treatment guideline or the Interferon Committee for combined pegylated interferon-ribavirin treatment~* Contraindications in the summary of product characteristics of pegylated interferon alpha-2a and ribavirin~* Participants previously treated with pegylated interferon and/or ribavirin~* Hepatitis B and Human Immunodeficiency Virus co-infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pegasys + Copegus (Type: None): Treatment naive participants with confirmed chronic hepatitis C who are started on combined Pegasys-Copegus treatment in accordance with current guidelines and SPCs, and whose treatment has been approved by the Interferon Committee.

Based on this trial design, predict the completion outcome and termination type (if applicable).